EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs

Piotr Stasiak iD, Justyna Sopel, Artur Płóciennik iD, Oliwia Musielak iD, Julia Maria Lipowicz, Agnieszka Anna Rawłuszko-Wieczorek iD, Karolina Sterzyńska iD, Jan Korbecki iD, Radosław Januchowski iD

International Journal of Molecular Sciences · 17.06.2025 · 26 (12) · 5800

DOI: 10.3390/ijms26125800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.06.2025. Verfasst von Piotr Stasiak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Sciences, Faculty of Exact and Natural Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tetrahydroisoquinolines, Acridines, Neoplasm Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy resistance is a major obstacle in the treatment of ovarian cancer, often resulting in disease recurrence and poor prognosis for patients. A key contributor to this resistance is the overexpression of ATP-binding cassette (ABC) transporters, including breast cancer resistance protein (BCRP/ABCG2), which actively effluxes chemotherapeutic agents such as topotecan (TOP) or mitoxantrone (MIT), limiting their intracellular accumulation and efficacy. This study investigated the potential of elacridar (GG918), a potent dual P-gp and BCRP inhibitor, to overcome drug resistance in ovarian cancer cell lines. Both TOP-sensitive and TOP-resistant ovarian cancer cells were grown in two-dimensional (2D) monolayers and three-dimensional (3D) spheroid models to better mimic the tumor microenvironment. The expression of the ABCG2 gene was quantified via qPCR and BCRP protein levels were assessed by western blotting and immunofluorescence. Drug response was evaluated using MTT viability assays, while BCRP transporter activity was examined using flow cytometry and microscopic assessment of the intracellular retention of BCRP fluorescent substrates (Hoechst 33342 and MIT). In both 2D and 3D cultures, elacridar effectively inhibited BCRP function and significantly enhanced sensitivity to TOP. These findings suggest that elacridar can inhibit BCRP-mediated drug resistance in ovarian cancer cell models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsTetrahydroisoquinolinesAcridinesNeoplasm ProteinsATP Binding Cassette Transporter, Subfamily G, Member 2Drug Resistance, NeoplasmHumansCell Line, TumorCell Culture Techniques, Three DimensionalCell Culture TechniquesAntineoplastic AgentsCell Survival

Stichwörter der Autor:innen

ABC transporters activitybreast cancer resistance protein (BCRP)chemotherapy resistanceelacridarmolecular inhibitorsmultidrug resistance (MDR)ovarian cancerthree-dimensional (3D) cell culture

Substanzen

ElacridarTetrahydroisoquinolinesAcridinesABCG2 protein, humanNeoplasm ProteinsATP Binding Cassette Transporter, Subfamily G, Member 2Antineoplastic Agents

Autor:innen und Institutionen

  • Institute of Biological Sciences, Faculty of Exact and Natural Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland.
  • The Doctoral School of Exact and Technical Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland.
  • Institute of Health Sciences, Collegium Medicum, University of Zielona Góra, 65-417 Zielona Góra, Poland.
  • Department of Histology and Embryology, Doctoral School, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
  • Department of Histology and Embryology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.

ORCID-Profile: Piotr Stasiak, Artur Płóciennik, Oliwia Musielak, Agnieszka Anna Rawłuszko-Wieczorek, Karolina Sterzyńska, Jan Korbecki, Radosław Januchowski

Förderung

  • National Science Centre

Zitieren

APA

Stasiak, P., Sopel, J., Płóciennik, A., Musielak, O., Lipowicz, J. M., Rawłuszko-Wieczorek, A. A., Sterzyńska, K., Korbecki, J., & Januchowski, R. (2025). Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs. International Journal of Molecular Sciences, 26(12), 5800. https://doi.org/10.3390/ijms26125800

Vancouver

Stasiak P, Sopel J, Płóciennik A, Musielak O, Lipowicz JM, Rawłuszko-Wieczorek AA, et al. Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs. International Journal of Molecular Sciences. 2025;26(12):5800. doi:10.3390/ijms26125800

BibTeX
@article{Stasiak2025,
  author = {Stasiak, Piotr and Sopel, Justyna and Płóciennik, Artur and Musielak, Oliwia and Lipowicz, Julia Maria and Rawłuszko-Wieczorek, Agnieszka Anna and Sterzyńska, Karolina and Korbecki, Jan and Januchowski, Radosław},
  title = {Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5800},
  doi = {10.3390/ijms26125800}
}
Kostenlos starten →